Stories
FSSAI Issues Notices to Dr. Reddy’s, Nestle, and Others Over Questionable Advertisements
C
CNBC Awaaz•08-10-2026, 20:56
FSSAI Issues Notices to Dr. Reddy’s, Nestle, and Others Over Questionable Advertisements
- •FSSAI issued notices to prominent companies including Dr. Reddy’s, Nestle Health Science, Flipkart, and Amazon over misleading advertisements.
- •The notices target claims related to 'CELEVIDA GLP+' linking the product to GLP-1/GIP therapies and lean muscle preservation.
- •FSSAI raised objections regarding the brand name 'CELEVIDA GLP+', stating it creates a misleading association for consumers.
- •The authority questioned claims such as helps maintain lean muscle, supports muscle strength, and preserve lean mass.
- •FSSAI has demanded a formal response from the concerned companies regarding these advertisements and medical claims.
Key Questions Answered
FSSAI issued notices regarding non-compliant advertisements and claims associated with the product 'CELEVIDA GLP+' and its connection to GLP-1/GIP therapies.
The authority raised objections over claims suggesting the product helps maintain lean muscle, supports muscle strength, preserves lean mass, and provides high protein support during weight loss or GLP-1/GIP therapies.
FSSAI stated that the brand name, alongside claims linked to GLP-1/GIP therapies, could create a misleading association between the product and those specific medical therapies among consumers.
